Randomized trial of adjuvant zoledronic acid in postmenopausal women with high-risk breast cancer

Clinical Breast Cancer

Volumn 10, Issue 6, 2010, Pages 471-476

  Leal, Ticiana ^a   Tevaarwerk, Amye ^a   Love, Richard ^b   Stewart, James ^c   Binkley, Neil ^d   Eickhoff, Jens ^e   Parrot, Benjamin ^a   Mulkerin, Daniel ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

Adjuvant therapy; Bone mineral density

Indexed keywords

TAMOXIFEN; ZOLEDRONIC ACID; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTHRALGIA; ARTICLE; BONE DENSITY; BREAST ADENOCARCINOMA; CALCANEUS; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FATIGUE; FEMALE; FEMUR NECK; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; OVERALL SURVIVAL; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; BREAST TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; LUMBAR VERTEBRA; MIDDLE AGED; PATHOLOGY; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CALCANEUS; CHEMOTHERAPY, ADJUVANT; DIPHOSPHONATES; DISEASE-FREE SURVIVAL; FEMALE; FEMUR NECK; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; LUMBAR VERTEBRAE; MIDDLE AGED; NEOPLASM STAGING; POSTMENOPAUSE; RISK FACTORS; SURVIVAL ANALYSIS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 79952276263     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.3816/CBC.2010.n.062     Document Type: Article

References (20)

1. Keen RW. Burden of osteoporosis and fractures. Curr Osteoporos Rep 2003; 1: 66-70.
2. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
3. Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994; 9: 745-51. (Pubitemid 24130477)
4. Ottewell PD, Lefley DV, Coleman RE, et al. Evaluation of the molecular mechanisms for the sequence-dependent, synergistic anti-tumour effects of doxorubicin and zoledronic acid in breast cancer. Presented at: the: 31st Annual San Antonio Breast Cancer Symposium; December 10-14, 2008; San Antonio, TX. Abstract 2151.
5. Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339: 357-63. (Pubitemid 28363797)
6. Powles T, Paterson S, Kanis JA, et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002; 20: 3219-24. (Pubitemid 34831518)
7. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360: 679-91.
8. Winter MC, Thorpe HC, Burkinshaw R, et al. The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathological response exploratory evidence for direct anti-tumor activity in breast cancer. Presented at: the 31st Annual San Antonio Breast Cancer Symposium; December 10-14, 2008; San Antonio, TX. Abstract 5101.
9. Bundred NJ, Campbell ID, Davidson N, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole ZO-FAST study results. Cancer 2008; 112: 1001-10. (Pubitemid 351304583)
10. Eidtmann H, Bundred NJ, DeBoer R, et al. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST. Presented at: the 31st Annual San Antonio Breast Cancer Symposium; December 10-14, 2008; San Antonio, TX. Abstract 44.
11. Mobus V, Conrad B, Schneeweis A, et al. Gain study: A phase III trial to compare ETC versus EC-TX and ibandronate versus observation in patients with nodepositive primary breast cancer. J Clin Oncol 2009; 27 (15 suppl): 23s (abstract 568).
12. Mamounas EP. NSABP Breast Cancer Clinical Trials: Recent Results and Future Directions. Clin Med & Res 2003; 1: 309-26.
13. Gould AL, Shih WJ. Sample size re-estimation without unblinding for normally distributed outcomes with unknown variance. Comm Statist-Theory & Methods 1992; 21: 2833-53.
14. Safra T, Bernstein Molho R, Stephansky I, et al. Effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole. J Clin Oncol 2009; 27 (15 suppl): 30s (abstract 599).
15. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone mineral density substudy. Lancet Oncol 2008; 9: 840-9.
16. Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008; 26: 4875-82
17. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-22. (Pubitemid 46698462)
18. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med 2007; 357: nihpa40967.
19. de Klerk G, van der Velde D, van der Palen J, et al. The usefulness of dual energy X-ray and laser absorptiometry of the calcaneus versus dual energy X-ray absorptiometry of hip and spine in diagnosing manifest osteoporosis. Arch Orthop Trauma Surg 2009; 129: 251-7.
20. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996; 14: 2738-46. (Pubitemid 26329660)